Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149759 · ClinicalTrials.gov registry record · NA
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
A NA study of Atopic Dermatitis and Eczema, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01149759: Completed NA study of Atopic Dermatitis and Eczema, sponsored by Rockefeller University.
NCT01149759 is a NA study of Atopic Dermatitis and Eczema that has completed, run by Rockefeller University. The registered enrollment target is 9 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01149759, a NA study of Atopic Dermatitis and Eczema, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune suppression and pathological correlation of cyclosporine A in these patients in order to determine the extent to which immune activation drives the pathological epidermal phenotype.
Primary Outcome
SCORAD ("SCORing Atopic Dermatitis") is a clinical tool for assessing the severity (i.e., extent, intensity) of atopic dermatitis (AD) as objectively as possible with scores ranging from 0-100. The higher the score indicates more severe AD. For this outcome the SCORAD change score is computed as an absolute number which is comparing improvement in the SCORAD score of participants at week 12 compared to their SCORAD score at baseline.
Conditions Studied
Interventions
- DRUG Cyclosporine A
Study Locations (1)
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-12 |
| Phase | NA |
What the finished NCT01149759 record still lists
NCT01149759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Cyclosporine A is the first listed.
NCT01149759 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01149759 about?
NCT01149759 is a clinical study titled "Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy". Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune sup...
What is the current status of trial NCT01149759?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2010-06. Estimated completion is 2014-12.
What conditions does trial NCT01149759 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT01149759?
The interventions under investigation include: Cyclosporine A (DRUG).
Who is sponsoring clinical trial NCT01149759?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01149759 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01149759's enrollment target sits among peer trials
9 148th of 150 higher than 3 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
-
Topical Treatment for Atopic Dermatitis
RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
COMPLETED · NA
-
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
COMPLETED · NA
-
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia